On our mission to develop better medicines, we have secured some valuable collaborations
Our collaborations and partnerships include:
In November 2021, we entered into a multi-target agreement covering five vaccine research programs, three within cancer vaccines, and two within infectious disease vaccines.
In December 2022, we entered into a clinical supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive head and neck cancer. Under the terms of the agreement, MSD will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
In May 2024, the agreement was expanded to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll HPV16-positive high-risk patients with locally advanced cervical cancer undergoing chemoradiotherapy.
In February 2019, Nykode entered a collaboration with Roche to explore a combination of Nykode’s cancer vaccine VB10 and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with advanced cervical cancer. Both companies retained ownership of their respective compounds during the clinical collaboration. The Phase 2 study enrolled 52 women and was completed in November, 2023.
In May 2023, the agreement was extended to include a two-arm randomized, double-blind, placebo-controlled Phase 2 selection trial to evaluate the efficacy and safety of VB10.16 alone or in combination with atezolizumab (Tecentriq®) in patients with HPV16-positive, PD-L1positive, recurrent or metastatic cervical cancer who are refractory to pembrolizumab with chemotherapy with/without bevacizumab. Nykode and Roche will each maintain ownership of their own compounds in the clinical collaboration.
In 2015, we entered into a license and supply agreement with Pharmajet for the Stratis® Intramuscular Needle-free Delivery System. Stratis has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications either intramuscularly or subcutaneously. Stratis was selected by Nykode for it’s safe and effective delivery of Nykode’s nucleic acid based technologies, preference by patients/caregivers, and offers a de-risked path to commercialization.
